ARDS (Acute Respiratory Distress Syndrome) — Acute respiratory distress syndrome (ARDS) pathophysiology (intro)

Historical Context & Motivation

For much of modern medical history, clinicians observed that patients suffering from severe trauma, sepsis, or massive transfusion could rapidly develop refractory hypoxemia, bilateral pulmonary infiltrates, and stiff, non-compliant lungs — yet they lacked a unifying framework to explain this devastating presentation. The recognition that a common pathological cascade, diffuse alveolar damage (DAD), underlies these clinical features led to the formal description of what we now call acute respiratory distress syndrome (ARDS). Understanding the history behind ARDS is essential because each milestone refined our diagnostic criteria, guided ventilatory strategies, and ultimately improved survival rates from roughly 70% mortality down to approximately 30–40% in contemporary practice.

Despite decades of research, ARDS remains a syndrome — not a single disease — defined by its clinical presentation rather than a unique etiological agent. The central question that drives modern investigation is: How does an initial insult — whether pulmonary or extrapulmonary — trigger a stereotyped cascade of inflammation, alveolar-capillary barrier disruption, and impaired gas exchange? Answering this question is the foundation upon which rational therapeutic strategies are built.

Core Principles & Definitions

ARDS is fundamentally a syndrome of acute, diffuse, inflammatory lung injury that leads to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. To understand its pathophysiology, one must first internalize several core principles that govern normal alveolar function and then appreciate how each is disrupted during the development of ARDS.

Visual Explanation — Normal vs. ARDS Alveolus

The diagram above illustrates the fundamental contrast between healthy and injured alveoli. In the normal alveolus (left), the ultra-thin alveolar-capillary barrier — composed of type I epithelial cells, a shared basement membrane, and capillary endothelium — permits rapid diffusion of oxygen into the blood and carbon dioxide out. Surfactant, secreted by type II pneumocytes, lines the alveolar surface and prevents collapse by reducing surface tension according to the Law of Laplace. In the ARDS alveolus (right), the inflammatory cascade has disrupted both sides of the barrier. Endothelial injury increases vascular permeability, allowing protein-rich fluid and inflammatory cells — particularly neutrophils — to enter the interstitium and then the alveolar lumen. The leaked plasma proteins inactivate surfactant and polymerize into hyaline membranes, the histological hallmark of diffuse alveolar damage. These membranes further thicken the diffusion barrier, compound surfactant loss, and make the lung profoundly non-compliant.

Pathophysiological Mechanisms of ARDS

The Inflammatory Cascade

The development of ARDS can be triggered by either direct pulmonary insults (pneumonia, aspiration, inhalation injury) or indirect extrapulmonary insults (sepsis, pancreatitis, massive transfusion). Regardless of the inciting cause, the downstream pathophysiological cascade converges on a stereotyped inflammatory response. The initial insult activates alveolar macrophages, which release pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-8 (IL-8). These cytokines upregulate adhesion molecules (selectins, integrins) on the pulmonary capillary endothelium, facilitating neutrophil margination, adhesion, and transmigration into the interstitial and alveolar spaces.

Endothelial and Epithelial Injury

Once recruited, neutrophils release a potent arsenal of injurious mediators. Reactive oxygen species (ROS) — including superoxide anion (O₂⁻), hydrogen peroxide (H₂O₂), and hydroxyl radicals (OH·) — directly damage cell membranes through lipid peroxidation. Proteolytic enzymes such as elastase and matrix metalloproteinases (MMPs) degrade the extracellular matrix and basement membrane. The net result is a loss of barrier function on both sides of the alveolar-capillary membrane. Endothelial gaps allow fluid and macromolecules to leak into the interstitium, while epithelial disruption allows this edema fluid to flood the alveolar lumen itself.

Consequences for Gas Exchange

Three major physiological derangements follow from alveolar flooding and collapse. First, intrapulmonary shunting occurs when blood perfuses alveoli that are completely filled with fluid or collapsed — ventilation-perfusion (V/Q) ratio approaches zero in these units, and the resulting shunt is refractory to supplemental oxygen because there is no ventilated alveolus for oxygen to reach. Second, regions of lung with partial flooding develop severely decreased V/Q mismatch, contributing further to hypoxemia. Third, the thickened alveolar-capillary barrier impairs diffusion of oxygen (though CO₂, being 20× more soluble, is less affected initially). The combination of true shunt and V/Q mismatch explains why patients with ARDS characteristically develop severe, refractory hypoxemia — the hallmark clinical feature of the syndrome.

The Three Phases of ARDS

ARDS is not a static event but a dynamic process that evolves through three overlapping histological and clinical phases. Recognizing which phase predominates at a given point in a patient's illness is critical because it informs prognosis, ventilator management, and whether the patient may benefit from specific interventions such as corticosteroids or prone positioning.

During the exudative phase, the dominant process is acute inflammation with massive alveolar flooding. Histologically, one observes diffuse alveolar damage with hyaline membranes, edema, hemorrhage, and necrosis of type I pneumocytes. Clinically, this manifests as acute-onset bilateral opacities on chest imaging, profound hypoxemia with a low P/F ratio, and markedly reduced lung compliance. The proliferative phase represents the lung's attempt at repair. Type II pneumocytes — the stem cells of the alveolar epithelium — proliferate and differentiate to replace destroyed type I cells. Fibroblasts and myofibroblasts begin organizing the intra-alveolar exudate, and some patients show clinical improvement. However, excessive fibroblast activity can transition into the fibrotic phase, characterized by dense collagen deposition, obliteration of normal alveolar architecture, microcyst formation, and development of pulmonary hypertension from vascular remodeling. Patients entering this phase often have prolonged ventilator dependence and significantly higher mortality.

Worked Example — Assessing ARDS Severity

Consider the following clinical scenario: A 58-year-old patient is admitted to the ICU following emergency surgery for a perforated appendix complicated by fecal peritonitis. She develops progressive dyspnea and hypoxemia over the next 48 hours. Her current ventilator settings include FiO₂ of 0.70, PEEP of 10 cmH₂O, and a tidal volume of 360 mL (she has a predicted body weight of 60 kg). Her ABG shows PaO₂ of 68 mmHg and PaCO₂ of 38 mmHg. Plateau pressure is 32 cmH₂O. Chest X-ray reveals bilateral opacities not fully explained by effusions or atelectasis, and echocardiography shows normal left ventricular function.

Direct vs. Indirect ARDS — Etiology Comparison

ARDS etiologies are traditionally divided into direct (pulmonary) and indirect (extrapulmonary) causes. Although the final common pathway — diffuse alveolar damage — is similar, the initial site of injury differs, and this distinction has implications for lung mechanics, imaging patterns, and potentially for response to certain therapies such as recruitment maneuvers and prone positioning. Understanding these differences provides the clinician with a more nuanced framework for managing individual patients.

Connections to Advanced Concepts

Understanding the introductory pathophysiology of ARDS provides the scaffolding for several advanced topics that you will encounter in critical care medicine. These include the concept of ventilator-induced lung injury (VILI), advanced ARDS phenotyping, and emerging targeted therapies. The table below previews how introductory concepts connect to these more advanced areas of study.

As you advance in your understanding, you will learn that the mechanical ventilator — while life-saving — can itself perpetuate and amplify lung injury through mechanisms collectively termed ventilator-induced lung injury (VILI). These include volutrauma (overdistension of aerated regions), atelectrauma (repetitive opening and collapse of unstable alveoli), and biotrauma (mechanotransduction of injurious forces into an amplified inflammatory response). Gattinoni's concept of the 'baby lung' — the notion that only a small, variably located fraction of the total lung remains aerated and thus receives the entire tidal volume — is the conceptual basis for why low tidal volumes relative to predicted body weight protect against VILI. This foundational understanding links directly back to the compliance equation you encountered earlier: when functional lung volume is small, even a modest tidal volume generates dangerous transpulmonary pressures.

Practice Problems

ARDS Pathophysiology — Summary